VICTORIA , April 2, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of Yasmina Noubia Abdiche, Ph.D., as Chief Scientific Officer, effective April 2020 . Dr. Abdiche will, among other responsibilities, lead the Company's global research and development teams.
"We are excited to have Dr. Abdiche join the ImmunoPrecise team," said Dr. Jennifer Bath , IPA's President and CEO. "She has a distinguished background in therapeutic antibody discovery and a strong track record of advancing drugs to the clinic. With over 15 years of industry experience Dr. Abdiche is a highly respected, strategic and skilled thought leader with solid scientific and business acumen."
Most recently, Dr. Abdiche was CSO at Carterra, where she helped transition their LSA analytical antibody screening platform from concept through prototype to global commercialization. Dr. Abdiche previously served as a Research Fellow on the leadership team at Rinat-Pfizer where she led a team of scientists providing core support for biomolecular interaction analysis and played an active role on the governing committee for Pfizer's Postdoctoral Program. She is co-inventor of several therapeutic antibodies that entered clinical trials including a current, market-approved drug, Ajovy.
"I am thrilled to lead ImmunoPrecise's research and development programs and accelerate their pre-clinical pipeline," stated Dr. Yasmina Abdiche. "I am honored to work with the team of incredibly talented and experienced scientists at IPA."
Dr. Abdiche graduated from Oxford University with a Ph.D. in Biological Chemistry and a Master's degree in Chemistry. She completed postdoctoral research in Dr. David Myszka's laboratory at the University of Utah in Salt Lake City , where she optimized biosensor methods for characterizing small molecule interactions.
About ImmunoPrecise Antibodies Ltd. ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com.
News 
Market Data 
Discover 
